Purpose: Perampanel (PER) and lacosamide (LCM) are antiepileptic drugs (AEDs) approved for the adjunctive treatment of partial-onset seizures. At the time of market entry, information on clinical effectiveness of new AEDs is limited to results from pivotal trials, real-life or comparative data are missing. This analysis of data collected retrospectively in a German epilepsy center used unified evaluation criteria, and describes treatment outcomes with LCM and PER at 6 months. Methods: Results of the first 70 consecutive patients who had received LCM or PER after their market entries in Germany were compared. Outcome measures comprised 50% responder rates, seizure freedom, retention, and incidence of adverse events (AEs). Results: The mean number of previous AEDs was 8.7 in the PER group, and 7.3 in the LCM group. At 6 months, the 50% responder rate for all seizures was 48.6% for PER, and 28.6% for LCM, with seizure freedom in 14.3% of patients with PER, and 4.3% with LCM. Thirty-two AEs were reported for LCM, and 51 for PER, most commonly dizziness (22.9% of patients) for LCM, and somnolence/tiredness for PER (41.4%). AEs were reported as primary reason for discontinuation in 3 patients of the PER group. Retention rates were similar. Conclusions: This analysis describes initial comparative benefits of two newly available AEDs in two cohorts of patients with highly refractory epilepsies. Responder and seizure freedom rates were numerically higher for PER. The analysis suggests that new AEDs can provide a chance for seizure freedom in relevant subgroups of patients, despite previous failure of multiple AEDs.
Introduction
Antiepileptic drugs (AEDs) newly licensed for use as adjunctive therapy are usually reserved to treat patients with severely refractory epilepsies in specialized epilepsy centers, presenting with long-standing illness and multiple previous drug failures.
Information regarding efficacy, tolerability and safety for an AED at this stage mainly originates from randomized controlled trials (RCTs) designed to evaluate the efficacy of the drug compared to placebo, and to serve as basis to assess a drug's overall benefitrisk ratio in the regulatory context. The external validity of RCTs may be limited by factors like relatively short trial durations, the usage of fixed dose regimens with stable baseline medication, and rapid dose escalations [1] .
With regard to the even more complex question of comparative efficacy and tolerability, recent systematic reviews and metaanalyses indicate that comparisons of newer AEDs based on RCT data fail to consistently identify differences in efficacy and other outcome measures on a larger scale due to methodologic issues or the small magnitude of any difference in effect [2] [3] [4] . Consequently, pivotal trial data in the adjunctive setting appear to be of limited value for evaluating the utility of AEDs in routine practice and differentiating between drugs in this context. In addition, heterogeneity in, and lack of complete information regarding baseline conditions and patient refractoriness across AED registration trials conducted over the past twenty years [5] may further complicate conclusions regarding comparative AED outcomes, leaving the clinician widely uninformed regarding optimal drug choice for individual patients.
Against this background, the collection, evaluation, and timely communication of first post-marketing experiences with new AEDs in tertiary epilepsy centers, especially in traditional "early launch" countries like Germany, can be relevant early sources of information for physicians in Europe and other parts of the world, delivering valuable insights into a new drug's real-life benefit and providing relevant recommendations on, for example, approaches to clinical use beyond information contained in a drug's prescribing information [6, 7] . Still, comparative data based on real-life observations is scarce, as first-experience reports naturally focus on observations for single drugs after their respective market entries. Unless based on a uniform assessment protocol, post-hoc analyses of data collected across different centers appear to be of limited informative value in this respect due to variable depth of information, differences in observational periods, heterogeneous or undisclosed information regarding baseline conditions, or differing evaluation criteria.
For two of the newer AEDs, lacosamide (LCM), a novel sodium channel blocker approved for the adjunctive treatment of partialonset seizures (POS) with or without secondary generalization in patients aged 16 years and older in 2008, and perampanel (PER), a novel, selective non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptor antagonist approved for the adjunctive treatment of POS with or without secondary generalization in patients aged 12 years and older in 2012, and for the adjunctive treatment of primary generalized tonic-clonic seizures in patients with Idiopathic Generalized Epilepsy aged 12 years and older in 2015, first clinical experiences from the German tertiary Kork Epilepsy Center had been collected and published independently in 2012 (for LCM, Ref. [8] ) and 2014 (for PER, Ref. [9] ). Although both publications described favorable results for PER and LCM in groups of patients with difficult-to-treat epilepsies, comparability of the reported outcomes are impeded by a significant difference in the length of the reported follow-up period (6 months for PER vs. 12 months for LCM), some ambiguity regarding the operationalization of seizure outcomes, and incomplete or missing information regarding potentially influential factors like seizure situation at baseline, or detailed information regarding concomitant and previously failed AEDs. Particularly the latter aspect is of special interest, as it was shown that the efficacy of a newly introduced AED and the associated chance of seizure freedom appears to be strongly predetermined by the number of previously failed AEDs [10] .
To facilitate the comparability of first experiences for PER and LCM collected in the Kork Epilepsy Center in two cohorts comprising consecutive patients, who first had received these new AEDs after their introduction in Germany, and to further elucidate AED treatment and pre-treatment status of both cohorts at baseline, a retrospective analysis based on chart review of individual patients along predefined variables and with unified evaluation criteria was conducted, the results of which are reported in this manuscript.
Methods
2.1. Design, inclusion criteria, rationale for choice of cut-off date, and patient management This was a retrospective single center data collection based on individual chart review with subsequent analysis of baseline demographic and epilepsy-related characteristics, and measures of AED efficacy, tolerability, and retention. Outcomes of the first 70 consecutive patients who had started PER in the Kork Epilepsy Center between September and December 2012, for whom followup data for a minimum of 6 months was available, were evaluated, and results were contrasted with the outcomes of the first 70 consecutive patients treated with LCM who had started the drug in September 2008. A 6 month data cut-off was defined, ending for PER in June 2013.
This cut-off date was chosen to avoid potential influences of factors beyond clinical considerations, especially related to future disparate drug accessibility, as it was announced at the end of June 2013, that PER would be withdrawn from the German market. This followed the ruling of the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), the highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany, that no evidence of an additional benefit of PER over comparative therapies had been provided. The G-BA commented that the presented clinical studies were not appropriate to assess the additional benefit, as the G-BA-defined comparative therapy had not been implemented. The decision was based on new legislation aimed at regulating the German drug market, effective from 2011 only, thus impacting PER, but not LCM.
Follow-up frequency was consistent with routine clinical practice and was usually between three and six months. At each follow-up visit, seizure details (based on seizure logs maintained by the patient), side effects, and complications since the last visit were retrieved. Clinical management of patients was performed by BJS and CK. Dosage of anticonvulsive co-medication was kept stable during the time patients received LCM or PER. Both drugs were dosed based on individual seizure frequency/severity and tolerability.
Parameters and data entry
An observational plan was prepared beforehand, detailing scope of the analysis, methods and operationalization of outcome measures. Variables to be assessed were defined in accordance with the observational plan, and prior to data collection. Chart review and data entry was performed by an experienced epileptologist (CK) by means of a standardized evaluation sheet in Excel.
The following baseline data was collected: gender, age, etiology (structural/metabolic; unknown; other), time since diagnosis (in years), seizure frequency for simple partial seizures, complex partial seizures, secondarily generalized seizures, and total seizure count (per month) before the introduction of PER or LCM into the therapeutic regimen, respectively. Furthermore, all concomitant and previous AEDs were to be specified; the Excel sheet comprised a list of 21 specific AEDs plus an "other" category, for which information on a "current" or "previous" use was to be derived from available patient charts.
The following outcome variables were to be completed: Response (defined as a minimum of 50% reduction in seizure frequency vs. baseline; yes/no), for all seizure types, and for secondarily generalized tonic-clonic (SGTC) seizures, as far as sufficient information was available for the latter; seizure freedom (for a minimum of 3 months prior to the cut-off date; yes/no), for all seizure types, and for SGTC seizures, as far as sufficient information was available for the latter; drug retention at 6 months (yes/no); if not retained, primary reason for discontinuation [adverse event (AE); insufficient efficacy, other]; if not retained: duration of treatment with PER or LCM, respectively (in weeks). For the evaluation of AEs within the evaluation period of 6 months, a list of 8 AE qualities was compiled based on AEs reported in the PER and LCM publications [8, 9] , which were: Somnolence/tiredness, dizziness, ataxia, irritability, falls, cognitive slowing, depression, nausea, and one "other" category. Finally, the information on the maintenance dose for PER or LCM achieved at 6 months was to be recorded, in milligram per day.
Statistical analysis
After all data had been extracted by the investigator and single queries were resolved, the completed Excel sheets were transferred to the Eisai Biostatistics department for analysis. Summary statistics with mean, standard deviation, median, minimum and maximum values, and lower and upper quartiles where appropriate were calculated for continuous variables, as well as numbers and percentage of subjects, with the total treatment group or relevant subgroup subject number as denominator for categorical variables. No inferential statistics were performed due to the retrospective and descriptive nature of the analysis. In addition, line listings containing all relevant clinical information for individual patients were produced.
Results

Demographics and epilepsy-specific variables at baseline
Baseline demographic and epilepsy-related characteristics are depicted in Table 1 . Both groups appeared to be comparable with regard to age and etiology. The PER group contained more female patients (58.6% vs. 48.6% in the LCM group). Both groups consisted of patients with long epilepsy durations, with a mean of >20 years since diagnosis, without significant overlap (only two patients present in both cohorts). The total seizure counts at baseline were indicative of the presence of highly active epilepsies in both groups, with a higher monthly seizure rate reported for the PER group (median 19.0 vs. 7.0 in the LCM group). For the majority of patients in the LCM group (n = 40), only the total seizure number per month at baseline could be extracted from patient charts. Further details on the presence of SGTC seizures at baseline (seizure count >0) could only be retrieved for a small subset of patients with LCM (n = 7), which was deemed to be insufficient for further analysis. For the PER group, data on seizure frequency per month for SGTC seizures was documented to be >0 for 50% of patients at baseline, and was analyzed for response and seizure freedom in accordance with the observational plan.
Prior and concomitant AEDs at baseline
Details on previously used and discontinued AEDs, as well as concomitant AEDs at baseline are depicted in Table 2 , in order of the overall use in both groups combined. For both groups, a high number and a wide range of previously used and discontinued drugs were documented, with a higher overall exposure for the PER group (mean number 8.7, vs. 7.3 for LCM). All patients had been treated with at least two different AEDs before the introduction of PER or LCM. The exposure rates for previous and current use combined for the three most frequently administered AEDs LEV, LTG, and CBZ ranged between 81.4% for CBZ and 94.3% for LEV, and exposure rates for VPA, TPM, OXC, PHT, PB, and ZNS were still high and varied between 50% and 82.9%. Larger differences (>10%) between both groups were observed regarding the overall exposure to OXC (50% for the LCM group vs. 77.1% for the PER group), the exposure to PB (52.9% for the LCM group vs. 70% for the PER group), and, naturally, the exposure to LCM (0% in the LCM group vs. 71.4% in the PER group) and, as ESL was introduced in Germany in 2009, regarding ESL (0% in the LCM group vs. 24.3% in the PER group). Differences were also observed regarding the previous exposure to other, not prespecified AEDs, with 34.4% of patients of the LCM group vs. 51.4% of patients in the PER group having been treated with other drugs previously.
Concomitant AEDs differed between the groups regarding number and type. At baseline, patients in the LCM group received 1.7 concomitant AEDs, patients in the PER group 2.3 AEDs. More patients in the LCM group received only one AED at baseline (42.9%, vs. 15.7% in the PER group), whereas more patients in the PER group received three or four baseline AEDs (38.6%, vs. 11.4% in the LCM group). The most frequently used drugs in the LCM group were LEV (32.9%), OXC (27.1%), CBZ (22.9%), and LTG (18.6%), the order in the PER group was LEV (42.9%), LCM (30%), LTG (31.3%), and VPA, OXC, and PB (20% each). Of note, CBZ was only part of the baseline medication in 5.7% of patients of the PER group.
Maintenance doses at 6 months
Data on maintenance doses at 6 months were only available for 46/70 patients for LCM, and 50/70 patients for PER. The mean maintenance dose for LCM was 374.5 mg/day, ranging from 150 to 600 mg/day. The mean maintenance dose for PER was 8.6 mg/day, with doses between 4 and 14 mg/day administered.
Efficacy at 6 months
The 50% responder rate for all seizures at 6 months versus baseline was 48.6% for PER (34/70 patients), and 28.6% (20/70 patients) for LCM. Seizure freedom from all seizures for a minimum of the previous three months was reported for 14.3% for PER (10/70 patients), and 4.3% for LCM (3/70 patients). The responder rate for SGTC seizures vs. baseline for the PER group was 37.1% (13/35 patients) , with seizure freedom from SGTC seizures for a minimum of three months at the last visit in 22.9% (8/35 patients). 
Retention at 6 months and reasons for discontinuation
The retention rate at 6 months was similar for both groups, with 67.1% of patients still being treated with PER, and 65.1% with LCM. For the 23 patients who had discontinued PER within 6 months, insufficient efficacy was reported as primary reason in 18 patients (78%), whereas AEs were reported in 3 patients (13%) as primary reason for discontinuation. For the 24 patients who had discontinued LCM within the 6-month observational period, AEs were reported as primary reason for 12 patients (50%), and insufficient efficacy for 10 patients (41.7%). In patients with therapy discontinuations, treatment was stopped after a median of 10 weeks for LCM, and after 12 weeks for PER. Table 3 lists the AEs reported for both drugs within the evaluation period of 6 months as numbers of patients with a respective incident. Overall, 32 AEs were reported for LCM, and 51 for PER. The most common AE for LCM was dizziness, in 22.9% of patients, and somnolence/tiredness for PER, with 41.4% of patients.
Tolerability
Discussion
According to the present analysis, the use of newly approved AEDs for adjunctive therapy in the first months after regular market availability in a German epilepsy center is, almost exclusively, limited to groups of patients with severely refractory and highly active epilepsies.
Still, seizure outcomes seem to be favorable in subgroups of patients for both drugs, with PER treatment resulting in a numerically higher responder (48.6% vs. 28.6%) and seizure freedom rate (14.3% vs. 4.3%) in clinical practice, the latter assessed for a minimum of three months. After 6 months, about two-thirds of patients remained on treatment for both drugs. Where drug discontinuations occurred, this took place after a median of 10-12 weeks. Patients in the PER group appear to have been more difficult to treat at baseline, as indicated by a higher median total seizure count of 19.0 seizures per month (vs. 7.0 for LCM), a higher median frequency for SGTC seizures of 3.0 seizures per month (vs. 2.0 for LCM), a higher number of previously failed AEDs (8.7 for PER vs. 7.3 for LCM) , and the fact that PER was added more frequently to baseline regimens of three or four AEDs. Although more patients experienced AEs under PER, these were infrequently reported as a primary cause for drug discontinuations, suggesting that adverse events were generally manageable and did not outweigh the drug's perceived benefit. The higher load of baseline AEDs may also have contributed to a higher b Most frequent (in >5 patients) AEDs in this category were: sulthiame (n = 16), ethosuximide (n = 6), and mesuximide (n = 6) in the LCM group, and sulthiame (n = 20), ethosuximide (n = 16), mesuximide (n = 8), bromides (n = 8), rufinamide (n = 7), felbamate (n = 6), and lorazepam (n = 6) in the PER group. Somnolence/tiredness, n (%) 6 (8.6) 29 ( incidence of AEs with PER, by increasing the likelihood of exceeding individual tolerability thresholds. The results for the first 70 consecutive patients treated with LCM in the Kork Epilepsy Center described in this manuscript are largely in line with the larger data set of 107 patients observed over a longer period of 12 months [8] , suggesting reasonable predictive value of the 6 months data: the seizure freedom rate reported therein was similar to the 6-month results with 4.7%, the responder rate was slightly higher with 35.6%, and the incidence of the leading AE dizziness did not seem to increase within an additional 6 months observation time. A recent review [11] on results of LCM as adjunctive therapy in refractory epilepsies reports 50% responder rates between 18% and 69%, and seizure freedom rates between 1.7% and 26.2% in non-comparative prospective and retrospective audits. Similar wide ranges can be found in a recent review on first clinical experiences with PER collected in small-to medium-sized patient cohorts, reporting 50% responder rates between 9% and 89%, and seizure freedom rates between 0% and 22% [12] . This high variability of reported results, which may lead to lack of clarity among clinicians regarding the utility of a new drug, is multifactorial, and based on strong heterogeneities in outcome-relevant factors like population refractoriness, titration scheme and dosages used, length of observational period, operationalization of outcome measures, and, not least, in physicians' individual experience with new drugs, which inevitably is limited at the very beginning, and also distinct across epilepsy centers. Single center data collections, using same or similar designs and evaluation criteria, may be a more robust source of information in this regard, and, to a certain degree, may also allow for comparisons between new AEDs, although they may also be subject to outcome-relevant differences in, for example, baseline conditions, which may affect results, or make comparisons difficult [13] .
Equally, although some of the strengths of the present analysis include the definition of outcome measures, observational time, and overall comparable baseline conditions for both drugs with regard to population refractoriness and AED history, which was assessed in great detail, there are a number of limitations. It was run retrospectively, and data evaluation and entry was performed by one investigator who was not blinded toward study scope and treatment conditions. The number of observed cases is relatively small, the length of the observational period was limited to 6 months, and seizure freedom was assessed for a relatively short period of 3 months, leaving open questions regarding the stability of results in the longer term.
Still, we believe that this analysis yields some interesting aspects. It clearly shows that even in patients with a previous exposure to a maximum of lifetime AEDs, further trials with new AEDs are justified as a clinically relevant response can be achieved in individual patients. As 300 mg/day represent the initial target dose for LCM in the Kork Epilepsy Center, it is not surprising that the mean LCM maintenance dose was settled close to the upper range of the approved dose range of 400 mg/day, whereas for PER, a medium to upper medium dose range was reported at 6 month. Interestingly, some patients became seizure free with a dose of 4 mg/day PER only, which raises the question as to whether the mode of action rather than drug dose may be the mediating factor for response, particularly in patients with previous failure of multiple conventional AEDs. Interestingly, with regard to effect dimension, seizure freedom rates for PER in this analysis resemble the results of another single center retrospective study, which reported a 16% chance for seizure freedom with the introduction of new AEDs in apparently drug-resistant epilepsy; the most frequently used new AED in this study had been LEV, a drug with a novel and unique mechanism of action at that time [14] .
For the future, in the interest of an earlier and more informative reporting of first externally valid experiences with new drugs, larger scale prospective single and multi-center data collections could be envisaged, using unified evaluation criteria, which may also form the basis for post-hoc drug comparisons.
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